James Garber, MD
Surgical Oncology · Savannah, GANPI 1548357213
Payments from drug & device makers
What this record shows
This record is dominated by education: $6,000 of the $7,446 with a category attached, or 80.6%. Intuitive Surgical accounts for 95.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $6,020 and has fallen 99.3% since, to $42 in 2025.
Across 19 payments — averaging $391.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Acera Surgical, Inc.$153
- Biowound Solutions, Inc.$27
- Davol Inc.$26
- Novo Nordisk$20
- Integra Lifesciences Corporation$18
- plus $60 from 4 others
What the payments were for
- Travel & lodging$86612%
- Food & beverage$5808%
- Education$6,00081%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $7,142 |
| Acera Surgical, Inc. | 1 | $153 |
| Biowound Solutions, Inc. | 1 | $27 |
| Davol Inc. | 1 | $26 |
| Novo Nordisk | 1 | $20 |
| Integra Lifesciences Corporation | 1 | $18 |
| Covidien LP | 1 | $16 |
| Angiodynamics, Inc. | 1 | $15 |
| BD | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$6,000
- Da Vinci Surgical System$986
- Restrata Wound Matrix$153
How this compares
$7,446 in reported general payments places this provider in the 80th percentile of 43 surgical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 43 | $240 |
| Ondansetron OdtOndansetron | 15 | $169 |
| Neomycin Sulfate | 15 | $86 |
| Metronidazole | 15 | $23 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Savannah
- William BurakSavannah$2K
- Leonard HenrySavannah$467
- Howard ZarenSavannah$0
- Eddie AbdallaAtlanta$34K
- Atuhani BurnettAtlanta$23K
- Anita JohnsonWoodstock$18K
- Danny YakoubAugusta$17K
- Nicole KounalakisAtlanta$14K
- Sartaj SangheraMarietta$10K
- Barry RosemanAtlanta$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.